Ascentage Pharma Group International

SEHK:6855 Stock Report

Market Cap: HK$13.3b

Ascentage Pharma Group International Management

Management criteria checks 2/4

Ascentage Pharma Group International's CEO is Dajun Yang, appointed in Jan 2009, has a tenure of 15.92 years. total yearly compensation is CN¥4.78M, comprised of 94.7% salary and 5.3% bonuses, including company stock and options. directly owns 0.025% of the company’s shares, worth HK$3.31M. The average tenure of the management team and the board of directors is 6.1 years and 4.6 years respectively.

Key information

Dajun Yang

Chief executive officer

CN¥4.8m

Total compensation

CEO salary percentage94.7%
CEO tenure15.9yrs
CEO ownership0.02%
Management average tenure6.1yrs
Board average tenure4.6yrs

Recent management updates

Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year

May 03
Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year

Recent updates

Ascentage Pharma Group International's (HKG:6855) Shares Climb 26% But Its Business Is Yet to Catch Up

Sep 04
Ascentage Pharma Group International's (HKG:6855) Shares Climb 26% But Its Business Is Yet to Catch Up

Here's Why Ascentage Pharma Group International (HKG:6855) Can Afford Some Debt

Aug 26
Here's Why Ascentage Pharma Group International (HKG:6855) Can Afford Some Debt

Ascentage Pharma Group International's (HKG:6855) Shares Climb 29% But Its Business Is Yet to Catch Up

Jun 18
Ascentage Pharma Group International's (HKG:6855) Shares Climb 29% But Its Business Is Yet to Catch Up

Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year

May 03
Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year

Why We're Not Concerned Yet About Ascentage Pharma Group International's (HKG:6855) 30% Share Price Plunge

Mar 30
Why We're Not Concerned Yet About Ascentage Pharma Group International's (HKG:6855) 30% Share Price Plunge

Are Investors Undervaluing Ascentage Pharma Group International (HKG:6855) By 40%?

Feb 17
Are Investors Undervaluing Ascentage Pharma Group International (HKG:6855) By 40%?

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Dec 20
There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Ascentage Pharma Group International (HKG:6855) Is Making Moderate Use Of Debt

Oct 28
Ascentage Pharma Group International (HKG:6855) Is Making Moderate Use Of Debt

Some Analysts Just Cut Their Ascentage Pharma Group International (HKG:6855) Estimates

Aug 27
Some Analysts Just Cut Their Ascentage Pharma Group International (HKG:6855) Estimates

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Aug 23
There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Ascentage Pharma Group International (HKG:6855) Is Carrying A Fair Bit Of Debt

Jun 19
Ascentage Pharma Group International (HKG:6855) Is Carrying A Fair Bit Of Debt

Ascentage Pharma Group International (HKG:6855) Has Debt But No Earnings; Should You Worry?

Dec 04
Ascentage Pharma Group International (HKG:6855) Has Debt But No Earnings; Should You Worry?

Is Ascentage Pharma Group International (HKG:6855) A Risky Investment?

Aug 30
Is Ascentage Pharma Group International (HKG:6855) A Risky Investment?

Does Ascentage Pharma Group International (HKG:6855) Have A Healthy Balance Sheet?

Oct 04
Does Ascentage Pharma Group International (HKG:6855) Have A Healthy Balance Sheet?

CEO Compensation Analysis

How has Dajun Yang's remuneration changed compared to Ascentage Pharma Group International's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥360m

Mar 31 2024n/an/a

-CN¥643m

Dec 31 2023CN¥5mCN¥5m

-CN¥926m

Sep 30 2023n/an/a

-CN¥902m

Jun 30 2023n/an/a

-CN¥879m

Mar 31 2023n/an/a

-CN¥881m

Dec 31 2022CN¥4mCN¥4m

-CN¥883m

Sep 30 2022n/an/a

-CN¥848m

Jun 30 2022n/an/a

-CN¥812m

Mar 31 2022n/an/a

-CN¥797m

Dec 31 2021CN¥5mCN¥5m

-CN¥782m

Sep 30 2021n/an/a

-CN¥759m

Jun 30 2021n/an/a

-CN¥735m

Mar 31 2021n/an/a

-CN¥706m

Dec 31 2020CN¥4mCN¥4m

-CN¥678m

Sep 30 2020n/an/a

-CN¥922m

Jun 30 2020n/an/a

-CN¥1b

Mar 31 2020n/an/a

-CN¥1b

Dec 31 2019CN¥4mCN¥3m

-CN¥1b

Compensation vs Market: Dajun's total compensation ($USD655.28K) is above average for companies of similar size in the Hong Kong market ($USD494.88K).

Compensation vs Earnings: Dajun's compensation has increased whilst the company is unprofitable.

CEO

Dajun Yang (61 yo)

15.9yrs

Tenure

CN¥4,781,000

Compensation

Dr. Dajun Yang, M.D., Ph D Co-Founded Ascentage Pharma Group International in 2019 and serves as its Chairman and has been its Director since November 17, 2017 and serves as its CEO since July 2018. His...

Leadership Team

NamePositionTenureCompensationOwnership
Dajun Yang
Co-Founder15.9yrsCN¥4.78m0.025%
HK$ 3.3m
Shaomeng Wang
Co-Founderno dataCN¥1.17mno data
Ming Guo
Co-Founder15.6yrsno datano data
Thomas Knapp
Senior VP & General Counsel5.8yrsno datano data
Yifan Zhai
Chief Medical Officerno datano data0.041%
HK$ 5.4m
Douglas Fang
Senior Vice President of Preclinical Developmentno datano datano data
Jianfeng Wen
Senior Vice President of Pharmaceutical Scienceno datano datano data
Raymond Kmetz
Chief Business Officer5.8yrsno datano data
Yifei Zhu
Chief Commercial Officer1.7yrsno datano data
Cheung Ki Wong
Company Secretary6.4yrsno datano data

6.1yrs

Average Tenure

61yo

Average Age

Experienced Management: 6855's management team is seasoned and experienced (6.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Dajun Yang
Co-Founder7.1yrsCN¥4.78m0.025%
HK$ 3.3m
Shaomeng Wang
Co-Founder7.1yrsCN¥1.17mno data
Allen S. Lichter
Chairman of the Clinical Advisory Board1.9yrsno datano data
Marina Bozilenko
Independent Non-Executive Directorless than a yearno datano data
Paul A. Bunn
Member of Clinical Advisory Boardno datano datano data
David Sidransky
Independent Non-Executive Director3.8yrsCN¥510.00kno data
Jedd D. Wolchok
Member of Clinical Advisory Board3.7yrsno datano data
Arul M. Chinnaiyan
Member of Clinical Advisory Boardno datano datano data
Changqing Ye
Independent Non-Executive Director5.5yrsCN¥502.00kno data
Dazhong Lu
Non-Executive Director6.4yrsCN¥25.00kno data
Wei Ren
Independent Non-Executive Director5.5yrsCN¥502.00kno data
Asher A. Chanan-Khan
Member of Clinical Advisory Board1.9yrsno datano data

4.6yrs

Average Tenure

59yo

Average Age

Experienced Board: 6855's board of directors are considered experienced (4.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 04:54
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ascentage Pharma Group International is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yang HuangBofA Global Research
Jin ZhangChina International Capital Corporation Limited
Wangbin ZhouChina International Capital Corporation Limited